Comparative Pharmacology
Head-to-head clinical analysis: BRONKOMETER versus XOPENEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRONKOMETER versus XOPENEX.
BRONKOMETER vs XOPENEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.
Selective beta-2 adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing intracellular cyclic AMP levels.
Isoetharine mesylate 0.5% solution: 2-4 inhalations every 4 hours as needed via hand-held nebulizer or IPPB.
Nebulized solution: 0.63 mg or 1.25 mg 3 times daily every 6-8 hours; metered-dose inhaler: 2 inhalations (90 mcg per inhalation) 3 times daily every 6-8 hours.
None Documented
None Documented
Terminal elimination half-life: 2-3 hours; clinically, bronchodilation persists but dosing interval is 3-4 hours due to rapid onset and offset.
Terminal elimination half-life: 3.3-4.0 hours in adults. Clinically, twice-daily dosing is not recommended due to shorter half-life; every 4-6 hour dosing is standard for acute bronchodilation.
Renal: 10-15% unchanged; 70-80% as sulfate conjugates; biliary/fecal: <5%.
Renal: 80-100% as unchanged drug and metabolites (approximately 60% as unchanged levalbuterol, 20% as inactive sulfate conjugate). Fecal: <5%.
Category C
Category C
Bronchodilator
Bronchodilator